NovaBay Pharmaceuticals to Hold 2017 Second Quarter Conference Call on August 10, 2017
August 03 2017 - 6:50AM
Business Wire
NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a
biopharmaceutical company focusing on commercializing prescription
Avenova® for lid and lash hygiene in the domestic eye care market,
announces that it will report 2017 second quarter financial results
after market close on Thursday, August 10. Management will hold an
investment community conference call that day to discuss financial
results and provide a Company update.
DATE: Thursday, August 10 TIME: 4:30 p.m. ET / 1:30
p.m. PT DIAL IN: 800-608-8202 from within the U.S. 702-495-1913
from outside the U.S. Enter conference identification number
56306358
The live call also will be available at
http://novabay.com/investors/events. A replay of the call will be
available beginning two hours after its completion through 12:59
p.m. Eastern time September 10, 2017, by dialing 855-859-2056 from
within the U.S. or 404-537-3406 from outside the U.S. and entering
the conference identification number 56306358. The call will also
be archived at http://novabay.com/investors/events.
About NovaBay Pharmaceuticals, Inc.: Going Beyond
Antibiotics®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company
focusing on commercializing and developing its non-antibiotic
anti-infective products to address the unmet therapeutic needs of
the global, topical anti-infective market with its two distinct
product categories: the NEUTROX® family of products and the
AGANOCIDE® compounds. The Neutrox family of products includes
AVENOVA® for the eye care market, NEUTROPHASE® for wound care
market, and CELLERX® for the aesthetic dermatology market. The
Aganocide compounds, still under development, have target
applications in the dermatology and urology markets.
Stay informed on NovaBay's
progress:Download our Mobile InvestorApp from
the Apple Store or Google PlayLike us
on FacebookFollow us on TwitterConnect
with NovaBay on LinkedInJoin us on
Google+Visit NovaBay's Website
NovaBay ContactsFor NovaBay
Avenova purchasing information, please
contact:1-800-890-0329www.Avenova.com
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170803005218/en/
NovaBay Pharmaceuticals, Inc.Jack McGovernChief Financial
Officer510-899-8800jmcgovern@novabay.comorInvestor ContactLHA Investor RelationsJody
Cain310-691-7100jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Aug 2024 to Sep 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Sep 2023 to Sep 2024